US 12,064,436 B2
Methods of treating brain tumors using combination therapy
Joshua Murtie, Winchester, MA (US); Nelamangala Nagaraja, Lexington, MA (US); Brandon Nicolay, Manchester, MA (US); David Schenkein, Boston, MA (US); and Katharine Yen, Wellesley, MA (US)
Assigned to Servier Pharmaceuticals LLC, Boston, MA (US)
Appl. No. 16/619,526
Filed by SERVIER PHARMACEUTICALS LLC, Boston, MA (US)
PCT Filed Jun. 12, 2018, PCT No. PCT/US2018/037062
§ 371(c)(1), (2) Date Jan. 22, 2020,
PCT Pub. No. WO2018/231796, PCT Pub. Date Dec. 20, 2018.
Claims priority of provisional application 62/518,565, filed on Jun. 12, 2017.
Prior Publication US 2022/0362250 A1, Nov. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/04 (2006.01); A61K 31/53 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61K 41/00 (2020.01)
CPC A61K 31/53 (2013.01) [A61P 35/00 (2018.01); A61K 41/0038 (2013.01)] 23 Claims
 
1. A method for treating glioma characterized by the presence of an IDH1 mutation or an IDH2 mutation, wherein the IDH1 or IDH2 mutation results in accumulation of R(−)-2-hydroxyglutarate, in a patient in need thereof comprising administering to the patient (a) a compound of formula (I)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof; and (b) radiation therapy; in amounts effective for treating glioma, wherein said compound of formula (I), or a pharmaceutically acceptable salt thereof and the radiation are administered concurrently or sequentially.